News

MHRA approves Brukinsa for chronic lymphocytic leukemia and marginal zone lymphoma

Read time: 1 mins

Published:20th Jan 2023

BeiGene announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Brukinsa (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy

The MHRA authorization for CLL is based on two global Phase III clinical trials: SEQUOIA (NCT03336333)1, comparing Brukinsa against bendamustine plus rituximab (BR) in patients with previously untreated CLL, and ALPINE (NCT03734016), comparing Brukinsa against Imbruvica (ibrutinib) in patients with relapsed/refractory (R/R) CLL.

Condition: CLL/SLL

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa

UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy

1 mins

Drug news

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia

1 min

Drug news

Subcutaneous Ocrevus one-year data from OCARINA II study demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection

2 min

See all news